SGLT2抑制剂在狼疮肾炎患者中的前后对照回顾性队列研究
该回顾性前后对照研究纳入53例维持治疗下仍有残余蛋白尿的狼疮肾炎患者,比较SGLT2抑制剂启用前后12个月蛋白尿、eGFR、血红蛋白等指标轨迹。结果显示全队列蛋白尿减少37.6%,eGFR年下降斜率由-6.3改善至-2.9 ml/min/1.73 m2(P<0.001),血红蛋白和红细胞压积中位分别升高0.78 g/dl和2.33%。
要点
- 53例狼疮肾炎患者启用SGLT2i后全队列蛋白尿减少37.6%(95%CI -6.8%至-76.3%)。
- eGFR年斜率由启用前-6.3改善为启用后-2.9 ml/min/1.73 m2(P<0.001),应答者与非应答者均观察到此效应。
- 血红蛋白和红细胞压积中位分别升高0.78 g/dl和2.33%,记录到6例(12%)不良事件。
核心结论
- 在狼疮肾炎患者中,使用SGLT2i与蛋白尿减少相关,并观察到eGFR、血红蛋白和红细胞压积轨迹的有利变化,且不依赖于蛋白尿应答。
研究设计与样本
- 回顾性前后对照研究,纳入53例维持治疗下仍有残余蛋白尿的狼疮肾炎患者,中位年龄35岁(IQR 28-46),45例(85%)为女性。
- 在SGLT2i启用前后各12个月按季度登记蛋白尿、eGFR、血红蛋白、红细胞压积、白蛋白、抗dsDNA抗体和血清补体,采用线性混合模型评估各参数轨迹。
- 蛋白尿较SGLT2i启用后下降≥30%的患者定义为应答者。
主要发现
- SGLT2i启用时中位蛋白尿为1.7 g/g(IQR 1.0-3.0),eGFR为94 ml/min/1.73 m2(IQR 53-114),血红蛋白为13.4 g/dl(IQR 12.4-14.4)。
- SGLT2i启用前eGFR年斜率为-6.3 ml/min/1.73 m2(95%CI -5.7至-6.9),启用后为-2.9 ml/min/1.73 m2(95%CI -2.7至-3.1),P<0.001;该效应在应答者和非应答者中均观察到。
- 血红蛋白和红细胞压积中位分别升高0.78 g/dl(95%CI 0.76-0.81)和2.33%(95%CI 2.24-2.41)。
- 记录到6例(12%)不良事件,其中3例(6%)导致急诊评估或住院。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The effects of sodium-glucose transporter 2 inhibitors (SGTL2i) in patients with lupus nephritis (LN) remain poorly studied. This study aimed to assess the SGLT2i effects in patients with LN and residual proteinuria through a retrospective before-and-after study. METHODS: We included patients with LN and residual proteinuria under maintenance treatment. Proteinuria, estimated glomerular filtration rate (eGFR), haemoglobin, hematocrit, albumin, anti-double-stranded DNA antibodies and serum complements were registered quarterly 12 months before and after SGLT2 initiation. The trajectory of each parameter was evaluated by linear mixed models for repeated measurements. Patients were classified as 'responders' if proteinuria decreased by ≥30% after SGLT2i initiation. RESULTS: We evaluated 53 patients, median age of 35 years (IQR 28-46), 45 (85%) female. At SGLT2i initiation, the median proteinuria was 1.7 g/g (IQR 1.0-3.0), eGFR 94 ml/min/1.73 m2 (IQR 53-114) and haemoglobin 13.4 g/dl (IQR 12.4-14.4). After initiating SGLT2i, there was a 37.6% reduction in proteinuria (95%CI -6.8% to -76.3%) in the full cohort. Thirty-two (60%) patients were responders and 21 (40%) non-responders. Before SGLT2i, the annualized eGFR slope was -6.3 ml/min/1.73 m2 (95%CI -5.7 to-6.9) and -2.9 ml/min/1.73 m2 (95%CI -2.7 to-3.1) after SGLT2i initiation (P < 0.001). The effect on eGFR was observed in responders and non-responders. The median haemoglobin and hematocrit increased by 0.78 g/dl (95%CI 0.76-0.81) and 2.33% (95%CI 2.24-2.41), respectively. Six (12%) adverse events were recorded, three (6%) events led to emergency room evaluation or hospitalization. CONCLUSIONS: In lupus nephritis the use of SGLT2i was associated with decreases in proteinuria. Beneficial changes in eGFR, haemoglobin and hematocrit trajectories after SGLT2i initiation were observed, independent of the proteinuria response.
引用
- Ramírez-Mulhern I, Navarro-Sánchez V, Rivero-Otamendi E, et al. Effects of sodium-glucose transporter 2 inhibitors in patients with lupus nephritis: a before-and-after retrospective cohort study. Rheumatology (Oxford). 2026. PMID: 41100075. doi:10.1093/rheumatology/keaf548
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。